Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.

Xiangjun Chen,Yang Wan,Taoyou Zhou,Jiong Li,Yuquan Wei
DOI: https://doi.org/10.2217/IMT.12.144
2013-01-01
Immunotherapy
Abstract:and improve the survival time in a mouse model. Materials & methods: The mice were challenged with LPS and survival time was monitored from 0-96 h after LPS treatment. TNF-alpha, IL-6, IL-1 beta, HMGB1, nitric oxide (NO) and IL-10 concentration in serum were measured by ELISA. Myeloperoxidase activity, malondialdehyde, lung wet:dry weight ratio and lung permeability in lung tissues were detected. NF-kappa B, HMGB1 and inducible NO synthase in the lungs were detected by western blot. Results: UA markedly rescued lethality, improved survival time and lung pathological changes, inhibited TNF-alpha, IL-6, IL-10, HMGB1 and NO, and increased IL-10 expression. In addition, UA can also decrease myeloperoxidase, malondialdehyde, lung wet:dry weight ratio and lung permeability. UA attenuated NF-kappa B, HMGB1 and inducible NO synthase protein expression in the lungs. Conclusion: The results suggest that UA is capable of improving survival time and LPS-induced acute lung injury. UA has a potentially therapeutic role in septic shock.
What problem does this paper attempt to address?